Search Results - "BOSTOM, Andrew"

Physical Activity in Kidney Transplant Recipients: A Review by Takahashi, Ashley, Hu, Susie L., Bostom, Andrew

“…Physical activity has known health benefits and is associated with reduced cardiovascular risk in the general population. Relatively few data are available for…”
Get full text

Remnant cholesterol is prospectively associated with cardiovascular disease events and all-cause mortality in kidney transplant recipients: the FAVORIT study by Horace, Reuben William, Roberts, Mary, Shireman, Theresa I, Merhi, Basma, Jacques, Paul, Bostom, Andrew G, Liu, Simin, Eaton, Charles B

“…Abstract Background The cholesterol content of circulating triglyceride-rich lipoproteins is characterized as remnant cholesterol, although little is known…”
Get full text

Physical Activity and Cardiovascular Risk among Kidney Transplant Patients by KANG, AUGUSTINE W, GARBER, CAROL EWING, EATON, CHARLES B, RISICA, PATRICIA M, BOSTOM, ANDREW G

“…PURPOSEResearch examining the relationship between physical activity (PA) and cardiovascular disease (CVD) risk factors among kidney transplant recipients…”
Get full text

Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial by Weiner, Daniel E., Park, Meyeon, Tighiouart, Hocine, Joseph, Alin A., Carpenter, Myra A., Goyal, Nitender, House, Andrew A., Hsu, Chi-yuan, Ix, Joachim H., Jacques, Paul F., Kew, Clifton E., Kim, S. Joseph, Kusek, John W., Pesavento, Todd E., Pfeffer, Marc A., Smith, Stephen R., Weir, Matthew R., Levey, Andrew S., Bostom, Andrew G.

“…Cardiovascular disease (CVD) is common and overall graft survival is suboptimal among kidney transplant recipients. Although albuminuria is a known risk factor…”
Get full text

Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial by Bostom, Andrew G, Carpenter, Myra A, Kusek, John W, Levey, Andrew S, Hunsicker, Lawrence, Pfeffer, Marc A, Selhub, Jacob, Jacques, Paul F, Cole, Edward, Gravens-Mueller, Lisa, House, Andrew A, Kew, Clifton, McKenney, Joyce L, Pacheco-Silva, Alvaro, Pesavento, Todd, Pirsch, John, Smith, Stephen, Solomon, Scott, Weir, Matthew

“…Kidney transplant recipients, like other patients with chronic kidney disease, experience excess risk of cardiovascular disease and elevated total homocysteine…”
Get full text

Physical activity and risk of cardiovascular events and all-cause mortality among kidney transplant recipients by Kang, Augustine W, Bostom, Andrew G, Kim, Hongseok, Eaton, Charles B, Gohh, Reginald, Kusek, John W, Pfeffer, Marc A, Risica, Patricia M, Garber, Carol E

“…Abstract Background Insufficient physical activity (PA) may increase the risk of all-cause mortality and cardiovascular disease (CVD) morbidity and mortality…”
Get full text

Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort by Merhi, Basma, MD, Shireman, Theresa, PhD, Carpenter, Myra A., PhD, Kusek, John W., PhD, Jacques, Paul, ScD, Pfeffer, Marc, MD, PhD, Rao, Madhumathi, MD, Foster, Meredith C., ScD, MPH, Kim, S. Joseph, MD, PhD, Pesavento, Todd E., MD, Smith, Stephen R., MD, Kew, Clifton E., MD, House, Andrew A., MD, Gohh, Reginald, MD, Weiner, Daniel E., MD, Levey, Andrew S., MD, Ix, Joachim H., MD, Bostom, Andrew, MD, MS

“…Background Mild hyperphosphatemia is a putative risk factor for cardiovascular disease [CVD], loss of kidney function, and mortality. Very limited data are…”
Get full text

Urine Fibrosis Markers and Risk of Allograft Failure in Kidney Transplant Recipients: A Case-Cohort Ancillary Study of the FAVORIT Trial by Ix, Joachim H., MD, MAS, Katz, Ronit, DPhil, Bansal, Nisha, MD, Foster, Meredith, PhD, Weiner, Daniel E., MD, Tracy, Russell, PhD, Jotwani, Vasantha, MD, Hughes-Austin, Jan, PhD, McKay, Dianne, MD, Gabbai, Francis, MD, Hsu, Chi-yuan, MD, Bostom, Andrew, MD, Levey, Andrew S., MD, Shlipak, Michael G., MD

“…Background Kidney tubulointerstitial fibrosis marks risk for allograft failure in kidney transplant recipients, but is poorly captured by estimated glomerular…”
Get full text

Blood Pressure, Chronic Kidney Disease Progression, and Kidney Allograft Failure in Kidney Transplant Recipients: A Secondary Analysis of the FAVORIT Trial by Malhotra, Rakesh, Katz, Ronit, Weiner, Daniel E, Levey, Andrew S, Cheung, Alfred K, Bostom, Andrew G, Ix, Joachim H

“…Abstract BACKGROUND In chronic kidney disease, intensive systolic blood pressure (SBP) control reduces mortality at a cost of greater acute kidney injury risk…”
Get full text

The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD by Malhotra, Rakesh, Katz, Ronit, Hoofnagle, Andrew, Bostom, Andrew, Rifkin, Dena E, Mcbride, Ruth, Probstfield, Jeffrey, Block, Geoffrey, Ix, Joachim H

“…Niacin downregulates intestinal sodium-dependent phosphate transporter 2b expression and reduces intestinal phosphate transport. Short-term studies have…”
Get full text

Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study by Kalil, Roberto S., Carpenter, Myra A., Ivanova, Anastasia, Gravens-Mueller, Lisa, John, Alin A., Weir, Matthew R., Pesavento, Todd, Bostom, Andrew G., Pfeffer, Marc A., Hunsicker, Lawrence G.

“…Elevated uric acid concentration is associated with higher rates of cardiovascular (CV) morbidity and mortality in the general population. It is not known…”
Get full text

Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels by BOSTOM, Andrew G, KRONENBERG, Florian, RITZ, Eberhard

“…Accurate renal function measurements are important for the diagnosis and treatment of kidney disease, proper medication dosing, interpretation of possible…”
Get full text

Hypophosphatemic Effect of Niacin in Patients without Renal Failure: A Randomized Trial by Maccubbin, Darbie, Tipping, Diane, Kuznetsova, Olga, Hanlon, William A, Bostom, Andrew G

“…Niacin administration lowers the marked hyperphosphatemia that is characteristic of renal failure. We examined whether niacin administration also reduces serum…”
Get full text

Safety Events in Kidney Transplant Recipients: Results from the Folic Acid for Vascular Outcome Reduction in Transplant Trial by Weir, Matthew R, Gravens-Muller, Lisa, Costa, Nadiesda, Ivanova, Anastasia, Manitpisitkul, Wana, Bostom, Andrew G, Diamantidis, Clarissa J

“…BACKGROUNDKidney transplant recipients are at increased risk for adverse safety events related to their reduced renal function and many medications. METHODSWe…”
Get full text

Binder Blinders—Niacin of Omission? by Bostom, Andrew G., MD, MS

Get full text

Effect of Folic Acid Fortification on Plasma Folate and Total Homocysteine Concentrations by Jacques, P.F, Selhub, J, Bostom, A.G, Wilson, P.W.F, Rosenberg, I.H

“…Background In 1996, the Food and Drug Administration issued a regulation requiring all enriched grain products to be fortified with folic acid to reduce the…”
Get full text

Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial by Dad, Taimur, MD, Tighiouart, Hocine, MS, Joseph, Alin, MD, MS, Bostom, Andrew, MD, Carpenter, Myra, PhD, Hunsicker, Lawrence, MD, Kusek, John W., PhD, Pfeffer, Marc, MD, PhD, Levey, Andrew S., MD, Weiner, Daniel E., MD, MS

“…Background Cardiovascular disease (CVD) is the leading cause of death in kidney transplant recipients. Whether aspirin may reduce the risk for CVD, death, and…”
Get full text

B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant Recipients by Jarolim, Petr, Claggett, Brian L, Conrad, Michael J, Carpenter, Myra A, Ivanova, Anastasia, Bostom, Andrew G, Kusek, John W, Hunsicker, Lawrence G, Jacques, Paul F, Gravens-Mueller, Lisa, Finn, Peter, Solomon, Scott D, Weiner, Daniel E, Levey, Andrew S, Pfeffer, Marc A

“…BACKGROUNDApproximately 200 000 kidney transplant recipients are living in the United States; they are at increased risk for cardiovascular and other adverse…”
Get full text

Sustained Hypophosphatemic Effect of Once-Daily Niacin/Laropiprant in Dyslipidemic CKD Stage 3 Patients by Ix, Joachim H., MD, Ganjoo, Prerna, MD, Tipping, Diane, MS, Tershakovec, Andrew M., MD, Bostom, Andrew G., MD, MS

Get full text

New Evidence for the Phosphorus-Lowering Effects of Niacin by Bostom, Andrew G., MD, MS

Get full text